STAT+: Pharmalittle: Merck KGaA probed by French court for misleading info; former Genentech scientists given prison terms over trade-secret theft
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is green apple caramel — a new addition to our pantry. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …
Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months, Reuters notes. Omicron-tailored shots by Pfizer and Moderna are already authorized by regulators in several countries. The U.S. has given the go-ahead for booster vaccines that target the currently circulating BA.4 and BA.5 subvariants of Omicron. Moderna maintained its bivalent booster has durability for at least three months and expects data from human trials of its BA.4/BA.5 targeted vaccine later this year.
Continue to STAT+ to read the full story…
